Trillium Therapeutics Responds to Market Activity
February 28 2020 - 12:30PM
At the request of IIROC ("Investment Industry Regulatory
Organization of Canada"),
Trillium Therapeutics Inc.
(the
“Company”) (NASDAQ/TSX: TRIL) wishes
to confirm that it is not aware of any material, undisclosed
information related to the Company that would account for the
recent increase in the market price and level of trading volume of
its common shares.
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
Company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “do not eat” signal that cancer cells frequently use to
evade the immune system.
The Company’s pipeline also includes a
preclinical STING (stimulator of interferon genes) agonist program.
As previously announced, the program is earmarked for
out-licensing.
For more information visit:
www.trilliumtherapeutics.com
Company Contact:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627 x232james@trilliumtherapeutics.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2023 to Apr 2024